Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Lannett Encouraged by Levothyroxine Development in Florida
March 1st, 2008
Lannett Company, Inc. (AMEX: LCI) said it is encouraged by a legal development in Florida that could remove generic Levothyroxine Sodium from the state's negative drug formulary. An administrative judge in Florida recently found that the inclusion of Levothyroxine on the state's negative drug formulary is an invalid exercise of legislative authority and that the product should be removed from the negative formulary. When a drug is included on Florida's negative formulary, pharmacists cannot substitute a generic version for a prescribed brand version. Lannett's levothyroxine sodium tablets are immediately available to pharmacies in Florida and offer...
Source: Law & Health Weekly (2008-03-01)
|
